RAFFLES MEDICAL GROUP LTD
BSL.SI
Raffles Medical Group - Bear For A Couple More Years
- Post analyst briefing, we understand from management that its hospitals in China would likely take three years to reach a positive EBITDA.
- We now turn bearish on Raffles Medical as near-term growth is mainly supported by rental income instead of organic growth; therefore we think there is a lack of an upside catalyst in the near term.
- Downgrade to SELL with a DCF-derived TP SGD1.10 (from SGD1.49) implying 14% downside.
Near term growth supported by rental income rather than organic growth.
- We believe the current valuation for Raffles Medical is high given that the Singapore healthcare scene continues to face slowdown in demand. Holland V medical centre was fully let out by 2Q17. Yet, despite a rental income booster from Holland V, revenue from healthcare services still fell by 1.1% in 2Q, implying a stronger decline in core revenue.
- On the hospital services side, revenue grew marginally at 0.3% in 2Q However, management cited that some of the foreign patients who came for diagnosis could not afford the treatment, leading to a single digit percentage decline in inpatient numbers. We think there might be a structural decline in inpatient load moving forward if the economic outlook in the region remains weak.
- Henceforth, while we expect an uplift in FY18F revenue driven by the hospital extension (open in 4Q17), we think most of it is still coming from rental income as 50% of the new space would be let out.
Bear for a couple more years before China delivers.
- Chongqing hospital and Shanghai hospital would probably begin their operations in 2H18F and 2H19F respectively. Management cited that a typical Chinese hospital would need three years to reach a positive EBITDA but losses should not wipe out 30-40% of the group’s profit.
- Previously, we had used the average operational cost of existing listed Chinese hospitals as a gauge for Raffles Medical potential start- up expenses. Given the new guidance from management, we think the “blue sky” scenario presented in our previous report from 25 April is too optimistic: Raffles Medical Group : Near-Term Headwinds.
Change in forecast
- Change in forecast as we now project each hospital in China to generate an operating loss of about SGD10m and SGD14m for its first two years of operations.
- We now incorporated the estimated results from the Chinese hospitals into our model. Together with a slower growth in domestic healthcare demand, we reduced our FY17-19F PATMI by 4%, 22% and 26% respectively.
Downgrade to SELL with a DCF-derived TP SGD1.10 (from SGD1.49).
- We downgrade as we think that the current valuation of 32x FY18F P/E is too high given that:
- Downgrade to SELL with a DCF-derived TP SGD1.10 (from SGD1.49). We downgrade as we think that the current valuation of 32x FY18F P/E is too high given that:
- Near-term earnings support is coming from non-core rental income;
- Domestic healthcare demand is likely to see structural decline;
- Start-up costs from the Chinese hospitals venture are going to be a drag especially in the first two years.
Juliana Cai CFA
RHB Invest
|
http://www.rhbinvest.com.sg/
2017-08-01
RHB Invest
SGX Stock
Analyst Report
1.10
Down
1.490
